Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2021-09-09 Report Publication Anno…
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is an official announcement released via RNS (Regulatory News Service) with the title "Notice of Results and Investor Presentation". It explicitly states that the company "will announce its unaudited interim results for the six months ended 30 June 2021 on Thursday, 30 September 2021" and details an accompanying investor webinar/presentation. Since this document is an announcement *about* future results and a presentation, and not the full results document (IR) or the presentation itself (IP), it fits the definition of a Report Publication Announcement (RPA). It is announcing the publication of the Interim Results (IR) and the Investor Presentation (IP) at a later date, and also describes the presentation event itself. Given the content focuses on announcing the timing of results and a related presentation event, RPA is the most precise fit, as it signals the upcoming release of other reports.
2021-09-09 English
New appointments to Scientific Advisory Board
Board/Management Information Classification · 99% confidence The document is identified by the header 'RNS Number : 8059K' and contains an announcement dated '06 September 2021'. The content details 'new appointments to the Scientific Advisory Board' of the Therapeutics Division. This type of announcement, concerning changes in scientific advisory personnel, does not fit neatly into the specific categories like 10-K, ER, or DIV. It relates to management/personnel structure, but specifically scientific advisory, which is often grouped with general corporate governance or regulatory updates. Since it is a formal announcement distributed via RNS (Regulatory News Service) and concerns personnel/governance updates that aren't explicitly covered by MANG (Board/Senior Management changes) or CGR (Governance Rules), the most appropriate general category for a non-standard, yet formal, corporate announcement distributed via RNS is 'Regulatory Filings' (RNS), as per the fallback rule, although it is closely related to Board/Management information. However, given the specific nature of announcing new scientific advisors, it is a corporate update. Since 'MANG' is defined as 'Board of directors or senior management', and this is an advisory board, it leans towards a general regulatory announcement. The document explicitly states it is distributed via 'Reach, the non-regulatory press release distribution service of RNS'. This strongly suggests the 'RNS' code, which serves as the general regulatory/miscellaneous announcement category.
2021-09-06 English
Appointment of Chief Scientific Officer
Board/Management Information Classification · 99% confidence The document is a press release distributed via RNS (Reach service), dated September 2, 2021. The content announces the 'Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta's Therapeutics Division'. This is a change in senior management/board personnel. Reviewing the definitions, the 'Board/Management Information' category (Code: MANG) specifically covers 'Announcement of changes in the company's board of directors or senior management.' This perfectly matches the document's content.
2021-09-02 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, time-sensitive operational announcement related to trading halts or volatility controls on the exchange. This type of general regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory filing category, RNS (Regulatory News Service). The document length is short (1932 chars), but it is the primary content itself, not an announcement *about* another report.
2021-08-25 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1915 characters) and contains the header 'RNS Number : 7973J'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states that 'This information is provided by RNS, the news service of the London Stock Exchange' and is approved by the Financial Conduct Authority (FCA). This structure—a brief, time-sensitive announcement disseminated via the RNS system—fits the definition of a general regulatory announcement that doesn't fit a specific financial report category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-08-25 English
Directorate Change
Board/Management Information Classification · 99% confidence The document begins with an 'RNS Number' and is dated August 18, 2021. The primary subject is the announcement of a 'Directorate Change,' specifically the appointment of Dr. Mark Goldberg as a Non-executive Director. It includes commentary from the CEO and Chairman, and concludes with regulatory disclosures regarding the director's details as per AIM Rules. This content directly relates to changes in senior management/board composition. Therefore, the appropriate classification is Board/Management Information (MANG).
2021-08-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.